Clinical Trial

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-13; most recent amendment 2026-01-20.
Status change: Not Yet Recruiting → Recruiting 2024-05-16
Trial Details
NCT Number NCT05914545
Lead Sponsor Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Conditions Advanced and Metastatic Solid Tumor
Enrollment 121 participants
Start Date 2023-06-12
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-22